Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 42 National Univ. Hospitals to Investigate Mutual Drug Purchase Prices
November 29, 2010
- Towa: Sales, Profits Outperform Forecasts
November 29, 2010
- Miraca HD: Acquisition Drives Sales, Up 9.9%
November 29, 2010
- Long-Listed Products May Undergo Additional 5% Price Cut in 2012: Mr Sakai of Credit Suisse
November 29, 2010
- Fuji Pharma: Record-High Sales, Profits Driven by Diagnostics
November 29, 2010
- Eiken: Sales Up 0.9% with Double-Digit Increases in Profits
November 29, 2010
- Rasilez Ranked No. 1 in HP Market: RepTrack Survey
November 29, 2010
- Nippon Chemiphar: Generics Push Up Sales, Profits
November 29, 2010
- Eisai Aims at US$1 Bil. Sales for Eribulin
November 29, 2010
- Shionogi Targets 10% of Anti-Flu Market with RAPIACTA
November 29, 2010
- Towa to Embark on Biosimilars Business
November 29, 2010
- Otsuka: Abilify Props Up Sales, Profits
November 29, 2010
- JCR to Begin Multinational Clinical Trials for LSDs in FY2011: Mr Ashida
November 29, 2010
- Otsuka Wins Abilify Patent Lawsuit in the US
November 29, 2010
- JCR Boosts Production Capacity for Epoetin Biosimilar
November 29, 2010
- Tsumura: Sales, Profits Rise Due to Growth in Ethical Kampo Medicines
November 29, 2010
- Korosho to Ask Drug Firms to Develop 29 More Unapproved Drugs/Indications
November 29, 2010
- JPMA to Organize “Asian Liaison Conference”
November 29, 2010
- End of R&D Tax Break to Result in Tax Increases for Pharma Industry: PMDA
November 29, 2010
- BioWa Licenses POTELLIGENT Technology to Agensys
November 29, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…